Fosaprepitant
Sold as Ivemend, Fosaprepitant adco, Osapit, Focinv, Emetend, Fefprip, Fosaprepitant hetero
[3-[[(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-5-oxo-4H-1,2,4-triazol-1-yl]phosphonic acid
Drag to rotate. Structure from PubChem CID 135413538.
Background
Registration
- Applicants
- 4
- Registrations
- 7
- Schedule source
- Consolidated Schedules 06 July 2026
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Msd (Pty) LtdCancelled | Ivemend | 150 mg | 450871 | S4 | None |
| Adcock Ingram Critical Care (Pty) Ltd | Fosaprepitant adco, Osapit, Focinv | Not stated | 530442, 530443.442, 530444.442 | S4 | None |
| Accord Healthcare (Pty) Ltd | Emetend | 150 mg | 540865 | S4 | PIPIL |
| Hetero Drugs South Africa (Pty) Ltd | Fefprip, Fosaprepitant hetero | Not stated | 570152, 570153.152 | S4 | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Ivemend 150 MG EACH VIAL CONTAINS FOSAPREPITANT DIMEGLUMINE EQUIVALENT TO FOSAPREPITANT 150,0 mg | 150 mg | 45087145/5.7.2/0871 | Cancelled | S4 | None |
| Fosaprepitant adco EACH VIAL CONTAINS FOSAPREPITANT DIMEGLUMINE EQUIVALENT TO FOSAPREPITANT 150,0 mg | Not listed | 53044253/5.7.2/0442 | Registered | S4 | None |
| Osapit EACH VIAL CONTAINS FOSAPREPITANT DIMEGLUMINE EQUIVALENT TO FOSAPREPITANT 150,0 mg | Not listed | 530443.44253/5.7.2/0443.442 | Registered | S4 | None |
| Focinv EACH VIAL CONTAINS FOSAPREPITANT DIMEGLUMINE EQUIVALENT TO FOSAPREPITANT 150,0 mg | Not listed | 530444.44253/5.7.2/0444.442 | Registered | S4 | None |
| Emetend 150 MG EACH VIAL CONTAINS FOSAPREPITANT DIMEGLUMINE EQUIVALENT TO FOSAPREPITANT 150,0 mg | 150 mgPowder for solution for infusion | 54086554/5.7.2/0865Approved 20 September 2022 | Registered | S4 | PIPIL |
| Fefprip EACH VIAL CONTAINS FOSAPREPITANT DIMEGLUMINE EQUIVALENT TO FOSAPREPITANT 150,0 mg | Not listed | 57015257/5.7.2/0152 | Registered | S4 | None |
| Fosaprepitant hetero EACH VIAL CONTAINS FOSAPREPITANT DIMEGLUMINE EQUIVALENT TO FOSAPREPITANT 150,0 mg | Not listed | 570153.15257/5.7.2/0153.152 | Registered | S4 | None |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Fosaprepitant dimeglumine equivalent to fosaprepitant
S4: Fosaprepitant
Consolidated Schedules 06 July 2026, line 6447
Pharmacological class: Anti-emetics and antivertigo preparations. (class 5.7.2)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
Schedule Verification
Emetend 150 MG, Accord Healthcare (Pty) Ltd is scheduled S4 in its official SAHPRA documents, read with 90% confidence.
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.